AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17598697 — intervention group
Group type: EXPERIMENTAL
Intervention: Melcam 15 mg tablets (test preparation)
Number of subjects: 24
Study 17598697 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation tablets
Number of subjects: 24
Study 15010183 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (1.75, 3.5, or 7.0 mg/kg)
Number of subjects: 11
Study 15010183 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (0.035, 0.07, 0.14 mg/kg)
Number of subjects: 11
Study 15010183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11558030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg)
Number of subjects: 300
Study 11558030 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (200 mg)
Number of subjects: 300
Study 11558030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 9549736 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1 (maximum 10 mg)
Number of subjects: 70
Study 9549736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7835358 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR or DDDR pacing
Number of subjects: 15
Study 7835358 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 15
Study 7835358 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 15
Study 7835358 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 15
Study 31414613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis group
Number of subjects: 51
Study 31414613 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 29274396 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan/Fludarabine with 2 Gy Total Body Irradiation (TBI)
Number of subjects: 100
Study 29274396 — intervention group
Group type: COMPARATOR
Intervention: Treosulfan/Fludarabine without Total Body Irradiation (non-TBI)
Number of subjects: 100
Study 28438414 — intervention group
Group type: EXPERIMENTAL
Intervention: BLTR (bilamellar tarsal rotation)
Number of subjects: 1000
Study 28438414 — intervention group
Group type: EXPERIMENTAL
Intervention: PLTR (posterior lamellar tarsal rotation)
Number of subjects: 1000
Study 28438414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PLTR and BLTR
Number of subjects: 1000
Study 26182779 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session oesophageal variceal band ligation (group B)
Number of subjects: 60
Study 26182779 — intervention group
Group type: COMPARATOR
Intervention: Multi-session oesophageal variceal band ligation (group A)
Number of subjects: 60
Study 23571785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus (PIM) cream
Number of subjects: 15
Study 23571785 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide cream (TA)
Number of subjects: 15
Study 21345423 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR protocol (preoperative education, early feeding, and mobilisation)
Number of subjects: 119
Study 21345423 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR protocol
Number of subjects: 119
Study 21345423 — intervention group
Group type: COMPARATOR
Intervention: Traditional model
Number of subjects: 119
Study 18384552 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% tetracycline 0.1% triamcinolone acetonide
Number of subjects: 44
Study 18384552 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide
Number of subjects: 44
Study 16818033 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular tissue biopsies for sperm extraction
Number of subjects: 35
Study 14524485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (354 ml/day)
Number of subjects: 112
Study 14524485 — intervention group
Group type: COMPARATOR
Intervention: Apple juice (354 ml/day)
Number of subjects: 112
Study 10738956 — intervention group
Group type: EXPERIMENTAL
Intervention: Posting signs in men's bathrooms
Number of subjects: 6
Study 10738956 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of signs
Number of subjects: 6
Study 8766671 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya formula (group A)
Number of subjects: 55
Study 8766671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysate of soya and bovine collagen (group B)
Number of subjects: 55
Study 8766671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysate of casein (group C)
Number of subjects: 55
Study 8766671 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 55
Study 1410946 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual treatment (manipulation, specific mobilization, muscle stretching, auto-traction, cortisone injections)
Number of subjects: 101
Study 1410946 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (standardized conventional but optimal activating treatment by primary health care teams)
Number of subjects: 101
Study 1410946 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual treatment
Number of subjects: 101
Study 2412056 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin, a serotonergic antagonist, administered for 5 days.
Number of subjects: 0
Study 2412056 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of Ketanserin.
Number of subjects: 0
Study 2412056 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (in vitro).
Number of subjects: 0
Study 29576307 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT vaccine (1 and 2 doses)
Number of subjects: 80
Study 29576307 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT vaccine (2 doses)
Number of subjects: 80
Study 29576307 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 80
Study 26903486 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW)
Number of subjects: 26
Study 26903486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IMWp)
Number of subjects: 26
Study 24972402 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week placement in aged care facilities
Number of subjects: 30
Study 22438232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (507 μg/d)
Number of subjects: 100
Study 22438232 — intervention group
Group type: COMPARATOR
Intervention: Control (202 μg/d)
Number of subjects: 100
Study 20442101 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (Radiesse)
Number of subjects: 102
Study 18671773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone and intranasal budesonide for 2 weeks, plus intranasal budesonide for 10 additional weeks
Number of subjects: 65
Study 18671773 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with glucocorticoids)
Number of subjects: 65
Study 15757851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment in patients with OH
Number of subjects: 45
Study 15757851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment in patients with SH
Number of subjects: 45
Study 15757851 — intervention group
Group type: COMPARATOR
Intervention: Control group (euthyroid)
Number of subjects: 45
Study 12477601 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 0.15 mg/min
Number of subjects: 47
Study 12477601 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 0.25 mg/min
Number of subjects: 47
Study 12477601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12477601 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (both doses)
Number of subjects: 47
Study 12477601 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (high dose)
Number of subjects: 47
Study 12477601 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 47
Study 10037559 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal temperature
Number of subjects: 266
Study 10037559 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected mean corneal temperature in males
Number of subjects: 266
Study 7745508 — intervention group
Group type: COMPARATOR
Intervention: One dose of synthetic surfactant
Number of subjects: 826
Study 7745508 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of synthetic surfactant
Number of subjects: 826
Study 2291059 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutacrine Oestrogénique
Number of subjects: 121
Study 2291059 — intervention group
Group type: COMPARATOR
Intervention: Parlodel
Number of subjects: 121
Study 6986110 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalant solution of metaproterenol
Number of subjects: 22
Study 6986110 — intervention group
Group type: COMPARATOR
Intervention: 0.5% solution of isoproterenol
Number of subjects: 22
Study 6986110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31430688 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral therapy (CBT)
Number of subjects: 168
Study 31430688 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy (CBT)
Number of subjects: 168
Study 31430688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 168
Study 28073322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-focused cognitive-behavioral coaching program
Number of subjects: 30
Study 28073322 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 26853210 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing racism in the past year (measured by the Measure of Indigenous Racism Experience)
Number of subjects: 541
Study 26853210 — intervention group
Group type: COMPARATOR
Intervention: Not experiencing racism
Number of subjects: 541
Study 24720928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue score 3-4 (n = 1,663)
Number of subjects: 3830
Study 24720928 — intervention group
Group type: COMPARATOR
Intervention: Fatigue score 0-1 (n = 535)
Number of subjects: 3830
Study 24720928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea score 3-4 (n = 1,843)
Number of subjects: 3830
Study 24720928 — intervention group
Group type: COMPARATOR
Intervention: Dyspnea score 1 (n = 292)
Number of subjects: 3830
Study 22964859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (RI) during bench press
Number of subjects: 22
Study 22964859 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute rest interval (RI) during bench press
Number of subjects: 22
Study 22964859 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute rest interval (RI) during bench press
Number of subjects: 22
Study 22964859 — intervention group
Group type: EXPERIMENTAL
Intervention: All RIs (1, 2, and 3 minutes)
Number of subjects: 22
Study 22964859 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of RI length
Number of subjects: 22
Study 20876217 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT (Screening, Brief Intervention and Referral for Treatment)
Number of subjects: 1132
Study 20876217 — intervention group
Group type: COMPARATOR
Intervention: Control (written handout)
Number of subjects: 1132
Study 18574113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 80
Study 18574113 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod 5%
Number of subjects: 80
Study 15748956 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a 44 mug SC tiw
Number of subjects: 15
Study 15748956 — intervention group
Group type: COMPARATOR
Intervention: IFN‐beta‐1a 30 mug IM qw
Number of subjects: 15
Study 12694346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy with simvastatin and ezetimide
Number of subjects: 9000
Study 10521634 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG‐assisted model of spine loading
Number of subjects: 12
Study 10521634 — intervention group
Group type: EXPERIMENTAL
Intervention: Task asymmetry and weight lifted
Number of subjects: 12
Study 8612386 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-ovotransferrin complex
Number of subjects: 0
Study 8612386 — intervention group
Group type: COMPARATOR
Intervention: Iron-gluconate formulation
Number of subjects: 0
Study 1992306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (n = 7; maximal dose, 30 mg/kg/day)
Number of subjects: 17
Study 1992306 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (n = 10; dose range, 2.5 to 12 g/day)
Number of subjects: 17
Study 1992306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (n = 7)
Number of subjects: 17
Study 6362210 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 60
Study 6362210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31864728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 48
Study 31864728 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 48
Study 30683803 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led social marketing intervention by adolescent creators (94 ACs, aged 12-14 years)
Number of subjects: 375
Study 30683803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 375
Study 28385939 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound device (n = 32)
Number of subjects: 62
Study 28385939 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound device (n = 30)
Number of subjects: 62
Study 25985806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 43 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 86 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: COMPARATOR
Intervention: Morphine IR 30 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75-100 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 125-175 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 100 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 200 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR 20 mg
Number of subjects: 0
Study 25985806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25208357 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouthrinse
Number of subjects: 354
Study 25208357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 354
Study 25208357 — intervention group
Group type: COMPARATOR
Intervention: Control (5% hydroalcohol solution)
Number of subjects: 354
Study 22665834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Care for Elders Unit
Number of subjects: 1632
Study 22665834 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1632
Study 19849720 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free system (Sumavel DosePro)
Number of subjects: 109
Study 19849720 — intervention group
Group type: COMPARATOR
Intervention: Needle-based system (Imitrex STATdose System)
Number of subjects: 109
Study 17323183 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Etidronate (400 mg daily for 2 weeks followed by 10 weeks off treatment, repeated four times)
Number of subjects: 414
Study 17323183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Etidronate (200 mg daily)
Number of subjects: 414
Study 17323183 — intervention group
Group type: COMPARATOR
Intervention: Control Group (1 microg alfacalcidol daily)
Number of subjects: 414
Study 15231556 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered CBT
Number of subjects: 274
Study 15231556 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274
Study 10947691 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational isodesox
Number of subjects: 112
Study 10947691 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl and midazolam
Number of subjects: 112
Study 8629755 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of injury control information in a physics course
Number of subjects: 203
Study 1631861 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine phosphate (10 mmol/L)
Number of subjects: 30
Study 1631861 — intervention group
Group type: COMPARATOR
Intervention: Plain cardioplegic solutions (control)
Number of subjects: 30
Study 6708394 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction (80 mmol Na/day)
Number of subjects: 21
Study 6708394 — intervention group
Group type: COMPARATOR
Intervention: Combined low-sodium/high-potassium diet (80 mmol Na/120 mmol K)
Number of subjects: 21
Study 6708394 — intervention group
Group type: COMPARATOR
Intervention: Moderate sodium restriction or combined low-sodium/high-potassium diet
Number of subjects: 21
Study 6708394 — intervention group
Group type: COMPARATOR
Intervention: Combined low-sodium/high-potassium diet
Number of subjects: 21
Study 31514043 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Behavior Therapy (TBT)
Number of subjects: 105
Study 31514043 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 105
Study 30203777 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix astragali and Salvia miltiorrhiza injection
Number of subjects: 600
Study 30203777 — intervention group
Group type: COMPARATOR
Intervention: Control group (local massage and rehabilitation training)
Number of subjects: 600
Study 27122141 — intervention group
Group type: EXPERIMENTAL
Intervention: CHILE Intervention
Number of subjects: 16
Study 27122141 — intervention group
Group type: COMPARATOR
Intervention: Control (comparison group)
Number of subjects: 16
Study 22475073 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person narratives
Number of subjects: 500
Study 22475073 — intervention group
Group type: COMPARATOR
Intervention: Third-person narratives
Number of subjects: 500
Study 22475073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both narrative types
Number of subjects: 500
Study 19847593 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral minimally-invasive incision
Number of subjects: 110
Study 19847593 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral incision
Number of subjects: 110
Study 18452346 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI 210 mg/2 weeks
Number of subjects: 0
Study 18452346 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI 300 mg/2 weeks
Number of subjects: 0
Study 18452346 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI 405 mg/4 weeks
Number of subjects: 0
Study 18452346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15821652 — intervention group
Group type: COMPARATOR
Intervention: Warm‐Touch
Number of subjects: 90
Study 15821652 — intervention group
Group type: COMPARATOR
Intervention: Thermamed SmartCare OP
Number of subjects: 90
Study 15821652 — intervention group
Group type: EXPERIMENTAL
Intervention: Allon 2001
Number of subjects: 90
Study 12844377 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate-containing toothpaste (1 mg/g)
Number of subjects: 30
Study 12844377 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 30
Study 10893090 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0
Study 10893090 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CPAP usage
Number of subjects: 0
Study 8850403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone, 1 to 2 mg/kg in a 10‐minute bolus, followed by an infusion of 420 mg in 24 hours.
Number of subjects: 40
Study 8850403 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amiodarone, 2.5 to 5 mg/kg in a 10‐minute bolus followed by an infusion of 900 mg in 24 hours.
Number of subjects: 40
Study 1507039 — intervention group
Group type: EXPERIMENTAL
Intervention: Delmopinol HCl 0.2%
Number of subjects: 45
Study 1507039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.2%
Number of subjects: 45
Study 1507039 — intervention group
Group type: EXPERIMENTAL
Intervention: Delmopinol HCl 0.2% and Chlorhexidine digluconate 0.2%
Number of subjects: 45
Study 2931266 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate glycol cream 0.05%
Number of subjects: 80
Study 2931266 — intervention group
Group type: COMPARATOR
Intervention: Desoximetasone ointment 0.25%
Number of subjects: 80
Study 31382822 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC)
Number of subjects: 600000
Study 31382822 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Density Lipoprotein Cholesterol (LDL-C)
Number of subjects: 600000
Study 31382822 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 600000
Study 31382822 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (ApoB)
Number of subjects: 600000
Study 29063516 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 45
Study 29063516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg every 12 h
Number of subjects: 45
Study 29063516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 26831173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine administered extradurally
Number of subjects: 22
Study 26831173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine administered via femoral and transgluteal sciatic electrolocation-guided nerve block
Number of subjects: 22
Study 26831173 — intervention group
Group type: COMPARATOR
Intervention: Comparison between the two groups using different loco-regional anaesthetic techniques
Number of subjects: 22
Study 25439693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine plus oxaliplatin (8 cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1 for 6 months)
Number of subjects: 1035
Study 25439693 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 1035
Study 25439693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine plus oxaliplatin
Number of subjects: 1035